ArticleMedical oncology (Northwood, London, England)2021
Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.
Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- HDAC inhibitor GCJ-490A modulates tumor microenvironment and synergizes with PD-1 antibody against breast and lung cancers in syngeneic murine models.Acta pharmacologica Sinica · 2026Article
- An integrated single-cell lung cancer atlas reveals distinct fibroblast phenotypes between adenocarcinoma and squamous cell carcinomas.NPJ precision oncology · 2026Article
- CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- A causal association between chemokines and the risk of lung cancer: a univariate and multivariate mendelian randomization study.Journal of cardiothoracic surgery · 2024Article
- Neutrophils Recruited by NKX2-1 Suppression via Activation of CXCLs/CXCR2 Axis Promote Lung Adenocarcinoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The Clinical Significance and Involvement in Molecular Cancer Processes of Chemokine CXCL1 in Selected Tumors.International journal of molecular sciences · 2024Review
- Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.Frontiers in immunology · 2024Review
- The role of CXCL family members in different diseases.Cell death discovery · 2023Review
- The Role of CXC Chemokines in Cancer Progression.Cancers · 2022Review
- Single-cell RNA sequencing reveals intratumoral heterogeneity and potential mechanisms of malignant progression in prostate cancer with perineural invasion.Frontiers in genetics · 2022Article
- Prognostic Significance of ANGPTL4 in Lung Adenocarcinoma: A Meta-Analysis Based on Integrated TCGA and GEO Databases.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance.International journal of inflammation · 2022Review
- Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines play a critical role in lung cancer progression and metastasis. In non-small cell lung cancer, the determination of dominant angiogenic CXCL-type chemokines may increase the efficacy of targeted therapy and modulate the prognosis of lung cancer. Also, chemokine and chemokine receptors shape the immune response in the cross-talk between both cancer cells and immune cells in the tumor microenvironment. In this computational evaluation study based on databases containing mostly RNA-seq analyses, it is aimed to determine the dominant angiogenic CXCL-type chemokines with the highest expression in lung adenocarcinoma tissues and particularly in non-small cell lung cancer cells. CXCL1, CXCL5, CXCL7, and CXCL8, which can potentially be co-regulated and associated with poor survival, and phagocyte infiltration including neutrophils and macrophages are predominantly identified in non-small cell lung cancer. Moreover, the receptors of these chemokines, CXCR1 (binding CXCL8) and CXCR2 (binding CXCL1, 5, 7, 8), are positively correlated with the infiltration of neutrophils and macrophages. With the discovery of the common regulatory mechanisms of these angiogenic chemokines and validation studies in clinical examples, the chemokine panels specific to non-small cell lung cancer will become clear and have a decisive role in the prognosis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.